ArticleMolecular oncology2026
Targeted modulation of IGFL2-AS1 reveals its translational potential in cervical adenocarcinoma.
Article in Molecular oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Cervical cancer remains a leading cause of mortality among women, particularly in low- and middle-income countries. Despite distinct prognoses and clinical outcomes between its main histological subtypes, squamous cell carcinoma (SCC) and adenocarcinoma (ADC), current treatment regimens remain largely similar, creating an urgent need for targeted therapeutic strategies based on molecular distinctions. To address this gap, the long noncoding RNA IGFL2-AS1 was investigated as a potential prognostic biomarker and therapeutic target in cervical adenocarcinoma. A translational approach was employed that integrated patient transcriptome data, in silico analysis from public databases, and in vitro validation. Using CRISPR/dCas9 technology, IGFL2-AS1 expression was modulated in HeLa (ADC) and SiHa (SCC) cell lines to assess its impact on cellular characteristics associated with tumorigenesis. In silico analysis revealed that IGFL2-AS1 expression was significantly reduced in ADC compared to SCC, and its low expression was consistently linked to poorer ADC prognosis and decreased patient survival. Notably, overexpression of IGFL2-AS1 in HeLa cells significantly reduced cell proliferation, migration, clonogenic survival, and enhanced sensitivity to cisplatin and doxorubicin. Conversely, IGFL2-AS1 repression in SiHa cells yielded no significant phenotypic changes, suggesting a context-dependent mechanism. IGFL2-AS1 is identified as a histological subtype-specific prognostic biomarker and promising therapeutic target for cervical adenocarcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.